Mid-market M&A firm secures deal for University of Sheffield spin-out with Certara
Livingstone is pleased to announce the sale of Simcyp Ltd to Certara for US$32.4m. Livingstone advised the shareholders of Simcyp on the transaction.
A successful spin-out from the University of Sheffield, Simcyp is the world’s pre-eminent provider of specialist modelling and simulation platforms for predicting the fate of drugs in virtual populations, including pediatric populations. Leading global pharma and biotech companies, including Pfizer, Johnson & Johnson and AstraZeneca, use Simcyp’s Simulator software to enhance their understanding of a drug’s progression through the body, to refine the scope of proposed clinical trials and to reduce the number of trials they must undertake. Simcyp’s products are recognised and used by major drug regulators around the world, including the FDA, EMA and MHRA.
The acquisition of Simcyp fills a gap between Certara’s two existing companies: Tripos, focused on drug discovery, and Pharsight, focused on drug development. Simcyp’s position in the vanguard of personalised medicine will also accelerate Certara’s translational medicine activities. Certara is an international group, headquartered in St. Louis, Missouri, and backed by San Francisco-based private equity investor Vector Capital.
John Evans, Managing Director at Simcyp commented: “Livingstone were absolutely committed to achieving the best result for the shareholders in this deal. Their tenacity and guidance throughout the process has helped complete a transaction which respects and protects Simcyp’s strong scientific culture, while helping provide for its future growth.”
Daniel Domberger, Partner at Livingstone who led the transaction, said: “Completing this transaction drew upon our expertise in both Healthcare and Technology, and the deal is an excellent example of our ability to find the right acquirer for a highly-specialist business and manage the complexities of cross-border M&A.”
Richard Fetterman, Partner at Livingstone, added: “Simcyp is the second highly-successful university spin-out we’ve sold this year, coming hot on the heels of the £27m sale of RADIL, the research and diagnostic laboratory of the University of Missouri’s College of Veterinary Medicine. We are delighted to have helped Simcyp’s shareholders achieve their objectives, and I am sure that this deal will secure a great future for the business.”